{"title":"胸腺瘤的病理学研究及靶向治疗进展","authors":"L. Jin","doi":"10.30683/1929-2279.2019.08.02","DOIUrl":null,"url":null,"abstract":": Thymoma is a rare tumor that was reclassified by the World Health Organization in 2015. Recent studies have made advances in molecular targeted therapies, such as c-KIT, EGFR, IGF-1R, PTEN, HDAC, VEGF and PD-L1. Additionally, new molecular markers such as CTV/CTS, GTF2I, Pax8 and DSG-3 have been used in the differential diagnosis of thymoma. This article reviews molecular pathogenesis of thymoma, application of molecular pathology in the differential diagnosis of thymoma and recent progress in targeted therapies for thymoma.","PeriodicalId":89799,"journal":{"name":"Journal of cancer research updates","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2019-12-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Recent Advances in Pathologic Research and Targeted Therapies of Thymoma\",\"authors\":\"L. Jin\",\"doi\":\"10.30683/1929-2279.2019.08.02\",\"DOIUrl\":null,\"url\":null,\"abstract\":\": Thymoma is a rare tumor that was reclassified by the World Health Organization in 2015. Recent studies have made advances in molecular targeted therapies, such as c-KIT, EGFR, IGF-1R, PTEN, HDAC, VEGF and PD-L1. Additionally, new molecular markers such as CTV/CTS, GTF2I, Pax8 and DSG-3 have been used in the differential diagnosis of thymoma. This article reviews molecular pathogenesis of thymoma, application of molecular pathology in the differential diagnosis of thymoma and recent progress in targeted therapies for thymoma.\",\"PeriodicalId\":89799,\"journal\":{\"name\":\"Journal of cancer research updates\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2019-12-25\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of cancer research updates\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.30683/1929-2279.2019.08.02\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of cancer research updates","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.30683/1929-2279.2019.08.02","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Recent Advances in Pathologic Research and Targeted Therapies of Thymoma
: Thymoma is a rare tumor that was reclassified by the World Health Organization in 2015. Recent studies have made advances in molecular targeted therapies, such as c-KIT, EGFR, IGF-1R, PTEN, HDAC, VEGF and PD-L1. Additionally, new molecular markers such as CTV/CTS, GTF2I, Pax8 and DSG-3 have been used in the differential diagnosis of thymoma. This article reviews molecular pathogenesis of thymoma, application of molecular pathology in the differential diagnosis of thymoma and recent progress in targeted therapies for thymoma.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
